echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [hot spot] st Changsheng issued a new announcement yesterday

    [hot spot] st Changsheng issued a new announcement yesterday

    • Last Update: 2018-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Since the vaccine event, the long-lived organisms have attracted much attention With the relevant departments stationed in Changsheng biological company since the investigation, it has been hit hard by the stock crash, the chairman of the board of directors being punished, the vice chairman of the board of directors being sued, the real estate being sealed up, the Environmental Protection Bureau affixing a ticket and so on It can be called "SKR" In the past two days, what's the current situation of living creatures? I'd like to invite you to read the following St Changsheng's stock fell and stopped for 17 consecutive days, with a market value of 17.1 billion yuan evaporated Photo source: company announcement today, Changsheng biology released a notice on abnormal stock trading fluctuations According to the announcement, the closing price deviation of the company's stock trading price has reached 12% in three consecutive trading days (August 3, 2018, August 6, 2018, August 7, 2018) According to relevant analysis, the market value has evaporated by 17.1 billion yuan Changsheng also said that during the period when the company recalled all batches of freeze-dried human rabies vaccine (Vero cell) within the validity period, it is expected that the recall will reduce the company's operating revenue by about 200 million yuan in the first half of 2018, with a net profit of about 140 million yuan, and the freeze-dried human rabies vaccine (Vero cell) shutdown will have a greater impact on the company's production and operation It is estimated that the operating revenue in the second half of 2018 will be reduced by about 540 million yuan 2 St Changsheng's vice chairman and spouse were sued, with a total amount of 630 million yuan Photo source: industrial securities company announced recently that industrial securities sued Zhang Minghao, a shareholder of St Changsheng, and Zhang qiucen, his spouse, to Fujian Higher People's court due to the dispute over repurchase of pledged securities, with a total amount of 630 million yuan Fujian Higher People's court accepted the lawsuit on August 1 At present, the results of the case have not been disclosed According to industry media, Zhang qiucen is the real name of Zhang Minghao's wife, while Zhang Minghao is the son of Gao Junfang, chairman of St Changsheng Prior to this (July 24), industrial securities issued a notice that Zhang Minghao and Yu chenpan, two natural person shareholders of Changsheng biology, pledged 178 million shares of industrial securities in total, and the amount to be purchased (financing scale) was 675 million yuan Among them, Zhang Minghao is the second largest shareholder of Changsheng biology, holding 174 million shares of the company, accounting for 17.88% of the total share capital, while 167 million shares of industrial securities are pledged, accounting for 95.87% of the share capital, 17.14% of the total share capital of the company, and the amount to be purchased back is 630 million yuan Up to now, relevant media have learned that the total amount of equity pledge of St Changsheng is 250 million shares, the equity pledge rate is 25.69%, accounting for 61.97% of circulating a shares Among them, most of the pledged equity is pledged by industrial securities The investigation team of the State Council introduced the progress of the vaccine case of Changsheng biological problem, saying that some vaccine batches were mixed with expired stock solution According to Xinhua news agency, the investigation team of the State Council announced the progress of the investigation on the illegal production of rabies vaccine by Jilin Changchun Changsheng company on August 7 According to the investigation team, Changchun Changsheng company has seriously violated the relevant provisions of the drug production quality management specifications and the national drug standards in the production of rabies vaccine since April 2014 Some batches were mixed with expired stock solution, the date and batch number were not filled in, and some batches were later marked with the production date At present, the recall work is in progress At the same time, it launched the notification and recall of the vaccine involved in the case sold abroad At the same time, the investigation team stressed that the case of Changchun Changsheng company, which is suspected of criminal offence and involved in regulatory responsibility, must be seriously investigated according to law Relevant investigation and follow-up work are in progress Information source: company announcement, network announcement information
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.